CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit GLP 1 Receptor Agonists Edge Peptides Structural Biophysics Guided Computational Design of Semaglutide Analogues to Enhance GLP 1R Activation Article (Preprint v1) by Wei Li Qeios Cagrilintide 10MG Simple Peptide Development of Cagrilintide, a Long Acting Amylin Analogue ScienceDirect